logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
TVTX
Travere Therapeutics, Inc.
56.34
2 x 41.32
2 x 71.82
bid
ask
-
0.47
0.83%
2 @ 04:00 PM
56.30 -0.04 (0.07%)
Ytd47.45%
1y283.00%
56.04
day range
57.61
14.42
52 week range
60.10
Open57.35Prev Close56.81Low56.04High57.61Mkt Cap5.24B
Vol1.53MAvg Vol2.55MEPS-0.50P/EN/AForward P/E11.71
Beta1.14Short Ratio6.90Inst. Own113.31%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0450-d Avg47.07200-d Avg35.001yr Est58.36

TVTX News

benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises
benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra
benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper
benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r
benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight a
benzinga.com
Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extens

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened protein
benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r
benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and m
benzinga.com
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67

HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) wit
benzinga.com
Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medici

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide dif